About Vestal Point Capital
Vestal Point Capital is a venture capital firm founded in 2023. It is primarily based out of New York City, United States. As of Mar 2026, Vestal Point Capital is an active investor, having invested in 4 companies, with 2 new investments in the last 12 months. It primarily invests in Post IPO round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Post IPO round of Alto Neuroscience Overall, Vestal Point Capital portfolio has seen 4 IPOs including key companies like Alto Neuroscience, enGene and LEXEO Therapeutics. A lot of funds co-invest with Vestal Point Capital, with names like Deep Track Capital sharing a substantial percentage of its portfolio. Vestal Point Capital has team of 7 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Post IPO
Portfolio IPOs
Deals in last 12 months
Vestal Point Capital's List of All Investments
Vestal Point Capital has a portfolio of 4 companies. Their most notable investments include Alto Neuroscience and enGene.Their portfolio spans across United States and Canada. They have invested in Life Sciences, High Tech, Enterprise Applications and 1 other sectors, across stages such as Post IPO stage. Here is the list of all investments by Vestal Point Capital:
AI-driven drug discovery platform for neurological diseases based on patients biomarkers. The company's platform measures patients biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to develop personalized psychiatric drugs. The company has pipeline of drugs including ALTO-100 for depression, ALTO-101 for neurodegenerative diseases, and more.
Key facts about Alto Neuroscience
- Founded Year: 2019
- Location: San Francisco (United States)
- Stage: Public
- Total Funding till date: $145M
- Employee Count: 87 as on Jul 31, 2026
- Investors: Perceptive Advisors, Commodore Capital and 36 Others
- Latest Funding Round: Post IPO, Mar 16, 2026, $*****
- Highlight: Public
2. enGene
EnGene is developing a non-viral gene therapy platform for the delivery of nucleic acid payloads to mucosal tissues. Its flagship platform DDX is a derived chitosan platform delivers DNA and various forms of RNA to broad tissue and disease applications. It has also developed a gut-optimized gene delivery formulation, Gene Pill for Short Bowel Syndrome (SBS). Gene Pill enables the oral delivery of DNA encoding a long-acting GLP-2 analog directly to GIT.
Key facts about enGene
Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases. It has developed a lead candidate LX1001 APOE4 inhibitor that helps in treating Alzheimer’s andother neurological disorders. Its drug candidate LX2006 cardiomyopathy helps in the treatment of Friedreich’s Ataxia & other genetic disorders. It also provides LX1004 CLN2 drug that plays an important role in treating Batten disease.
Key facts about LEXEO Therapeutics
- Founded Year: 2018
- Location: New York City (United States)
- Annual Revenue: $0 - $1M as on Dec 31, 2022
- Stage: Public
- Total Funding till date: $185M
- Employee Count: 96 as on Jul 31, 2026
- Investors: Lundbeck Foundation, Frazier Life Sciences and 26 Others
- Latest Funding Round: Post IPO, Oct 20, 2025, $*****
- Highlight: Public
Developer of gene therapy platform for Duchenne muscular dystrophy. The lead candidate SGT-001 is Microdystrophin, a synthetic version of the dystrophin gene which stabilizes the muscle membrane and dystrophin-glycoprotein complex. Also, developed a soft wearable device for mobility and help preserve muscle function.
Key facts about Solid Biosciences
- Founded Year: 2014
- Location: Cambridge (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2022
- Stage: Public
- Total Funding till date: $92.5M
- Employee Count: 166 as on Jul 31, 2026
- Investors: Bain Capital Life Sciences, RTW Investments and 18 Others
- Latest Funding Round: Post IPO, Mar 06, 2026, $*****
- Highlight: Public
Vestal Point Capital's Year-on-Year Investment Trends
In 2025, it made 2 investments, while as of Mar 2026, it has made 2 investments in this year. Its most recent first time investment was in Solid Biosciences and most recent follow-on round was in Alto Neuroscience.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 1 | 2 |
2025 | 2 | 0 | 2 |
2024 | 1 | 0 | 1 |
Vestal Point Capital's Investments by Stage
Vestal Point Capital has made 4 investments in Post IPO stage with an average round size of $103M.Vestal Point Capital's Investments by Sector
Vestal Point Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Consumer and Enterprise Applications. Notably, it has invested in 4 Enterprise (B2B) companies, 4 Tech companies and 1 Software company.Sector | No. of Investments |
|---|---|
Life Sciences | 4 |
High Tech | 2 |
Consumer | 1 |
Enterprise Applications | 1 |
Note: We have considered here, only first round of investments
Vestal Point Capital's Investments by Geography
Vestal Point Capital has made most investments in United States (3), followed by Canada where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 3 |
Canada | 1 |
Note: We have considered here, only first round of investments
Vestal Point Capital's recent investments
Vestal Point Capital has made 2 investments in 2026 so far - Alto Neuroscience and Solid Biosciences.Here are the most recent investments by Vestal Point Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 16, 2026 | United States | Post IPO | 6034 | [+5] | |
Mar 06, 2026 | United States | Post IPO | 8744 | [+5] | |
Oct 21, 2025 | United States | Post IPO | 6086 | [+2] | |
May 27, 2025 | United States | Post IPO | 1405 | ||
Oct 25, 2024 | Canada | Post IPO | 8685 | [+5] |
IPOs and Publicly Listed companies in Vestal Point Capital's Portfolio
4 of Vestal Point Capital's portfolio companies have become public. Alto Neuroscience got listed on the New York Stock Exchange (NYSE), in Feb 2024 at marketcap of $409M and LEXEO Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $277M.Here are Vestal Point Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 02, 2024 | Oct 21, 2025 | Post IPO | 7910 | |
Nov 03, 2023 | May 27, 2025 | Post IPO | 8767 | |
Nov 01, 2023 | Oct 25, 2024 | Post IPO | 8876 | |
Jan 26, 2018 | Mar 06, 2026 | Post IPO | 4967 |
Team profile of Vestal Point Capital
Vestal Point Capital has a team of 7 members located in United States. Vestal Point Capital's team does not sit on the board of any company as of now.Co-investors of Vestal Point Capital
Over the past 2 years, 80 investors have co-invested in Vestal Point Capital's portfolio companies. This includes funds and angels.
- Invested before Vestal Point Capital: Alexandria, HHS and 61 others have invested in rounds before Vestal Point Capital. There are 2 companies where Alexandria has invested before Vestal Point Capital and 2 companies where HHS has invested before Vestal Point Capital.
- Top Co-investors of Vestal Point Capital: 13 investors entered a company along with Vestal Point Capital. These include investors like Deep Track Capital (2 companies).
- Invested after Vestal Point Capital: A total of 4 investors have invested in Vestal Point Capital's portfolio after their investments. Top Investors include Dellora (1 company), Driehaus (1 company) and Spruce Street Capital (1 company).
Recent News related to Vestal Point Capital
•
Vestal Point Capital Leases 12K SF at Rockrose Development's 11 East 26th StreetCommercial Observer•Sep 03, 2026•Vestal Point Capital
•
Alto Neuroscience Announces $50 Million Private Placement Financingintelligence360•Nov 10, 2025•Vestal Point Capital, Alto Neuroscience, Perceptive Advisors, Commodore Capital and 1 other
•
Adagio Medical Announces Pricing of up to $50 Million Private Placement of SecuritiesBusiness Wire•Oct 15, 2025•Perceptive Advisors, Piper Sandler, Adagio Medical, Lake Street Capital Markets and 4 others
•
iBio Announces Pricing of $50 Million Public OfferingGlobeNewswire•Aug 19, 2025•iBio, Vestal Point Capital, SilverArc Capital, Adage Capital Management and 5 others
•
Lexeo Therapeutics Secures $80 Million Equity Financing for Cardiovascular Genetic Medicine DevelopmentGlobeNewswire•May 27, 2025•LEXEO Therapeutics, Frazier Life Sciences, Janus Henderson Investors, Woodline Partners and 4 others
•
Vestal Point Capital Increases Stake in Lexeo TherapeuticsMarketBeat•May 21, 2025•LEXEO Therapeutics, Vestal Point Capital
•
•
•
Vestal Point Capital LP Acquires New Shares in Ionis PharmaceuticalsMarketBeat•May 21, 2025•Ionis, Vestal Point Capital
•
Vestal Point Capital LP Increases Savara Inc. (SVRA) StakeMarketBeat•May 21, 2025•Savara Pharma, Vestal Point Capital
